ALSUntangled #72: Insulin

Andrew Brown, Carmel Armon, Paul Barkhaus, Morgan Beauchamp, Tulio Bertorini, Mark Bromberg, Javier Mascias Cadavid, Gregory T. Carter, Jesse Crayle, Eva L. Feldman, Terry Heiman-Patterson, Sartaj Jhooty, Alexandra Linares, Xiaoyan Li, Elise Mallon, Christopher Mcdermott, Tasnim Mushannen, George Nathaniel, Gary Pattee, Kaitlyn PierceAri Rappoport, Dylan Ratner, Lenka Slactova, Paul Wicks, Richard Bedlack*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review insulin, which has at least one plausible mechanism for slowing ALS progression. However, pre-clinical studies are limited and there have been no trials in PALS yet. Insulin use in patients without a metabolic need may cause very serious and potentially lethal side effects. While further studies to evaluate potential benefits may be warranted, at this time we cannot endorse insulin treatment to slow ALS progression.

Original languageAmerican English
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
DOIs
StateAccepted/In press - 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases.

Keywords

  • Amyotrophic lateral sclerosis (ALS)
  • insulin
  • metabolism
  • off-label treatment

Fingerprint

Dive into the research topics of 'ALSUntangled #72: Insulin'. Together they form a unique fingerprint.

Cite this